Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects With Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy and Mild Proliferative Diabetic Retinopathy

Next Previous
Search
Trial Profile

Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects With Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy and Mild Proliferative Diabetic Retinopathy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APX 3330 (Primary)
  • Indications Diabetic macular oedema; Diabetic retinopathy
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms ZETA-1
  • Sponsors Ocuphire Pharma

    • Most Recent Events

    • 10 Jul 2024 According to an Ocuphire Pharma Media Release, subset analysis from this study will be presented during the ASRS 42nd Annual Scientific Meeting .
    • 10 May 2024 According to an Ocuphire Pharma Media Release, a subpopulation analysis of ZETA-1 data in NPDR will be released.
    • 06 May 2024 According to an Ocuphire Pharma Media Release, data from this study was presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place May 5-9, 2024 in Seattle, Washington.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top